botox 200 enheder pulver til injektionsvæske, opløsning
abbvie a/s - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 200 enheder
botox 50 enheder pulver til injektionsvæske, opløsning
abbvie a/s - clostridium botulinum, type a toxin - pulver til injektionsvæske, opløsning - 50 enheder
virono 50 mg resoribletter, slimhindeklæbende
vectans pharma - aciclovir - resoribletter, slimhindeklæbende - 50 mg
zovir 200 mg tabletter
glaxosmithkline pharma a/s - aciclovir - tabletter - 200 mg
zovir 400 mg tabletter
glaxosmithkline pharma a/s - aciclovir - tabletter - 400 mg
zovir 800 mg tabletter
glaxosmithkline pharma a/s - aciclovir - tabletter - 800 mg
zovirax 80 mg/ml oral suspension
paranova danmark a/s - aciclovir - oral suspension - 80 mg/ml
tigecycline accord
accord healthcare s.l.u. - tigecycline - soft tissue infections; intraabdominal infections; bacterial infections; skin diseases, infectious - antibakterielle midler til systemisk brug, - tygecycline accord er angivet i voksne og i børn fra en alder af otte år til behandling af følgende infektioner (se punkt 4. 4 og 5. 1):komplicerede hud-og bløddelsinfektioner (cssti), undtagen diabetiske fod infektioner (se punkt 4. 4)kompliceret, intra-abdominale infektioner (ciai)tygecycline overenskomst bør kun anvendes i situationer, hvor andre antibiotika ikke er egnet (se afsnit 4. 4, 4. 8 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..
imcivree
rhythm pharmaceuticals netherlands b.v. - setmelanotide - fedme - antiobesity preparations, excl. diætprodukter - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.
aubagio
sanofi winthrop industrie - teriflunomide - multipel sclerose - selektive immunosuppressiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).